

Judit Várkonyi  
*Editor*

# The Myelodysplastic Syndromes

 Springer

# The Myelodysplastic Syndromes

Judit Várkonyi  
Editor

# The Myelodysplastic Syndromes

 Springer

*Editor*

Prof. Judit Várkonyi  
3rd Department of Internal Medicine  
Semmelweis University  
Kútvölgyi út 4, 1125 Budapest  
Hungary  
varkjud@kut.sote.hu

ISBN 978-94-007-0439-8 e-ISBN 978-94-007-0440-4

DOI 10.1007/978-94-007-0440-4

Springer Dordrecht Heidelberg London New York

Library of Congress Control Number: 2011921323

© Springer Science+Business Media B.V. 2011

No part of this work may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher, with the exception of any material supplied specifically for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work.

*Cover design:* deblik, Berlin

Printed on acid-free paper

Springer is part of Springer Science+Business Media ([www.springer.com](http://www.springer.com))

*“In memory of my late father Zoltán Várkonyi  
and with love and gratitude to my dear husband  
Janos Quittner and son Zoltán Quittner”*

# Preface

Myelodysplastic syndromes (MDS) are the most common hematological malignancies involving mainly the elderly. They are defined as clonal stem cell disorders and characterized by ineffective hematopoiesis involving one to all bone marrow cell lineages [1]. The dominant morbidity of MDS relates to symptomatic cytopenias.

According to various reports the annual incidence of MDS ranges widely from 2 to 12 per 100,000, increasing to 30–50 cases per 100,000 among persons aged 70 or older. It is believed that the true incidence of MDS has been underestimated and appears to be comparable to that of multiple myeloma and chronic lymphocytic leukemia [2, 3].

MDS may arise *de novo*, or as a result of previous environmental damage, or chemo- or radiotherapy with a peak incidence at 2–4 years following the initial exposure [4]. It might therefore be hypothesized that MDS arises due to cumulative environmental exposure in genetically predisposed individuals [5]. MDS may be regarded as a progression model in which the acquisition of genetic events occur by gain or loss of genetic material.

MDS was previously named “preleukemia” or “smoldering leukemia” with a lack of terminal cells due to high apoptosis rate and the subsequent failure of differentiation. In about 25% of all cases when MDS progresses to AML—stem cell apoptosis stops and the cells fail to differentiate, a process that has been widely studied. In the past decade much progress had been achieved. We know more about disease pathophysiology resulting in increased emphasis on patient care and the evolution of targeted therapy.

The chapters of this book offer updated knowledge on all clinically important aspects of the disease. Topics of great current interest are discussed by leading authors on MDS from different parts of the world. We would like to recommend this book to all those interested in this exciting and rapidly expanding field of hematology, including medical students and postgraduates.

Although MDS is a clonal disease it is not yet recognized as a malignant disease by the majority of health care systems. Consequently, access of MDS patients to novel, expensive and targeted therapeutic modalities is generally unsatisfactory. It is hoped that the present volume will increase awareness of the necessity of opti-

mal treatment beyond simple supportive measures and facilitate the introduction of optimal treatment adequately sponsored by decision makers in health care systems.

## References

1. Corey SJ, Minden MD, Barber DL, Kantarjian H, Wang JCY, Schimmer AD (2007) Myelodysplastic syndromes: the complexity of stem-cell diseases. *Nat Rev Cancer* 7:118–129
2. Rollison DE, Howlader N, Smith MT, Strom SS, Merritt WD, Ries LA, Edwards BK, List AF (2008) Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001–2004, using data from the NAACCR and SEER programs. *Blood* 2008 112(1):45–52
3. Germing U, Aul C, Niemeyer CM, Haas R, Bennett JM (2008) Epidemiology, classification and prognosis of adults and children with myelodysplastic syndromes. *Ann Hematol* 87:691–699
4. Raposa T, Várkonyi J (1987) The relationship between sister chromatid exchange induction and leukemogenicity of different cytostatics. *Cancer Detect Prev* 10(1–2):141–151
5. Willman C (2001) MDS/AML: models of genetic progression and clues to etiology. *Leukemia Res* 25(1):1 (Abstr. Or3)

Budapest, Hungary

Prof. Judit Várkonyi

# Contents

<b>1</b>	<b>The History of the Myelodysplastic Syndromes</b> .....	1
	Ray M. Lowenthal	
<b>2</b>	<b>Susceptibility to MDS: DNA Repair and Detoxification Genes</b> .....	5
	Claire Seedhouse and Nigel Russell	
<b>3</b>	<b>Myelodysplastic Syndromes/Neoplasms: Morphological and Immunohistochemical Features and Standard Evaluation</b> .....	25
	H.-P. Horny and P. Valent	
<b>4</b>	<b>Diagnostic Criteria and Classification of Myelodysplastic Syndromes</b> .....	43
	Peter Valent, Friedrich Wimazal, Wolfgang R. Sperr and Hans-Peter Horny	
<b>5</b>	<b>Cytogenetics of MDS</b> .....	55
	Detlef Haase, Christina Ganster, Christian Steidl, Katayoon Shirmeshan, Friederike Braulke and Julie Schanz	
<b>6</b>	<b>Molecular Changes in Myelodysplastic Syndrome</b> .....	87
	Florian Nolte and Wolf-K. Hofmann	
<b>7</b>	<b>Prognostic Scoring in MDS</b> .....	103
	Michael Pfeilstöcker	
<b>8</b>	<b>Flow Cytometry in Myelodysplastic Syndromes</b> .....	121
	C. Alhan, T. M. Westers, G. J. Ossenkoppele and Arjan A. van de Loosdrecht	
<b>9</b>	<b>MDS as an Autoimmune Process</b> .....	145
	W. Ingram, Y. Kordasti and G. J. Mufti	
<b>10</b>	<b>The Myelodysplastic Overlap Syndromes</b> .....	159
	W. Ingram and G. J. Mufti	



<b>11 Iron and Copper Metabolism in the Myelodysplastic Syndromes</b> .....	175
Judit Várkonyi, Gabriella Bekő, Zoltán Prohászka and István Karádi	
<b>12 Pathogenesis and Management of Iron Overload in MDS</b> .....	187
Chaim Hershko	
<b>13 Cytokines in MDS: Abnormalities and Treatment</b> .....	205
Howard S. Oster, Drorit Neumann and Moshe Mittelman	
<b>14 Therapeutic Modalities and New Molecular Targets in MDS</b> .....	219
Guillermo Garcia-Manero	
<b>15 Haematopoietic Stem Cell Transplantation in MDS for Adults</b> .....	239
Tamás Masszi	
<b>16 JMML and Myelodysplastic Syndrome in Children</b> .....	253
Henrik Hasle	
<b>Appendix</b> .....	279
<b>Index</b> .....	285

# Contributors

**C. Alhan** Department of Hematology, VU Institute for Cancer and Immunology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands

**Gabriella Bekó** 3rd Department of Internal Medicine, Semmelweis University, Kútvölgyi út 4, 1125 Budapest, Hungary

**Friederike Braulke** Abteilung Hämatologie/Onkologie, Georg-August-Universität Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany  
e-mail: fbraulke@med.uni-goettingen.de

**Christina Ganster** Abteilung Hämatologie/Onkologie, Georg-August-Universität Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany  
e-mail: christina.ganster@med.uni-goettingen.de

**Prof. Chief Guillermo Garcia-Manero MD** Section of Myelodysplastic Syndromes, Department of Leukemia, MD Anderson Cancer Center, University of Texas, 1515 Holcombe Blvd, PO Box 428, Houston, TX 77025, USA  
e-mail: ggarciam@mdanderson.org

**Detlef Haase** Abteilung Hämatologie/Onkologie, Georg-August-Universität Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany  
e-mail: haase.onkologie@med.uni-goettingen.de

**Dr. Henrik Hasle** Department of Pediatrics, Skejby Hospital, Aarhus University, 8200 Aarhus N, Denmark  
e-mail: hasle@dadlnet.dk

**Chaim Hershko MD** Department of Hematology, Shaare Zedek Medical Center, P. O. Box 3235, Jerusalem, Israel  
e-mail: hershkoc@netvision.net.il

**Wolf-K. Hofmann** Department of Hematology and Oncology, University Hospital Mannheim, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany

**H.-P. Horny** Institute of Pathology, Escherichstrasse 6, 91522 Ansbach, Germany  
e-mail: horny@patho-ansbach.de

**Dr. W. Ingram** Department of Haematology, University Hospital of Wales, Heath Park, Cardiff, CF14 4XW, UK  
e-mail: wendy.ingram@wales.nhs.uk

**István Karádi** 3rd Department of Internal Medicine, Semmelweis University, Kútvölgyi út 4, 1125 Budapest, Hungary

**Y. Kordasti** Department of Haematological Medicine, King's College London, London, UK

**Arjan A. van de Loosdrecht, MD, PhD** Department of Hematology, VU Institute for Cancer and Immunology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands  
e-mail: a.vandeloosdrecht@vumc.nl

**Ray M. Lowenthal AO, MBBS, MD, FRCP, FRACP, FACHPM** Department of Clinical Haematology and Medical Oncology and Menzies Research Institute Tasmania, Royal Hobart Hospital, Hobart, TAS, Australia  
Department of Medicine, University of Tasmania, 7000 Hobart, Australia  
e-mail: r.m.lowenthal@utas.edu.au

**Tamás Masszi** Department of Haematology and Stem Cell Transplantation, St. István and St. László Hospital of Budapest, St. László Campus, Gyáli út 5-7, 1097 Budapest, Hungary  
e-mail: tmasszi@laszlokorhaz.hu

**Moshe Mittelman** Department of Medicine, Tel Aviv Sourasky Medical Center, 6 Weizmann St., 64239 Tel Aviv, Israel  
e-mail: moshemt@tasmc.health.gov.il  
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

**G. J. Mufti** Department of Haematological Medicine, King's College London, London, UK

**Drorit Neumann** Department of Cell and Developmental Biology, Tel Aviv University, Sackler School of Medicine building, Ramat Aviv, Israel  
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

**Florian Nolte** Department of Hematology and Oncology, University Hospital Mannheim, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany  
e-mail: florian.nolte@medma.uni-heidelberg.de

**G. J. Ossenkoppele** Department of Hematology, VU Institute for Cancer and Immunology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands

**Howard S. Oster** Department of Medicine, Tel Aviv Sourasky Medical Center, 6 Weizmann St., 64239 Tel Aviv, Israel  
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv

**Michael Pfeilstöcker** 3rd Medical Department and L. Boltzmann Institute for Leukemia Research & Hematology, Hanusch Hospital, H. Collinstr 30, 1140 Vienna, Austria  
e-mail: michael.pfeilstoecker@wgkk.at

**Zoltán Prohászka** 3rd Department of Internal Medicine, Semmelweis University, Kútvölgyi út 4, 1125 Budapest, Hungary

**Prof. Nigel Russell** Department of Academic Haematology, University of Nottingham, Clinical Sciences Building, Nottingham University Hospitals—City Campus, NG5 1PB Nottingham, UK

**Julie Schanz** Abteilung Hämatologie/Onkologie, Georg-August-Universität Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany  
e-mail: j.schanz@med.uni-goettingen.de

**Dr. Claire Seedhouse** Department of Academic Haematology, University of Nottingham, Clinical Sciences Building, Nottingham University Hospitals—City Campus, NG5 1PB Nottingham, UK  
e-mail: claire.seedhouse@nottingham.ac.uk

**Katayoon Shirneshan** Abteilung Hämatologie/Onkologie, Georg-August-Universität Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany  
e-mail: shirneshan@med.uni-goettingen.de

**Wolfgang R. Sperr** Division of Hematology & Hemostaseology, Department of Medicine I, Medical University of Vienna and Ludwig Boltzmann Cluster Oncology, Waehringer Guertel 18-20, 1090 Vienna, Austria

**Christian Steidl** Department of Pathology, British Columbia Cancer Agency, 600 W 10th Avenue, V5Z 4E6 Vancouver BC, Canada  
e-mail: csteidl@bccancer.bc.ca

**P. Valent MD** Division of Hematology & Hemostaseology, Department of Medicine I, Medical University of Vienna and Ludwig Boltzmann Cluster Oncology, Waehringer Guertel 18-20, 1090 Vienna, Austria  
e-mail: peter.valent@meduniwien.ac.at

**Judit Várkonyi** 3rd Department of Internal Medicine, Semmelweis University, Kútvölgyi út 4, 1125 Budapest, Hungary  
e-mail: varjud@kut.sote.hu

**T. M. Westers** Department of Hematology, VU Institute for Cancer and Immunology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands

**Friedrich Wimazal** Division of Hematology & Hemostaseology, Department of Medicine I, Medical University of Vienna Waehringer Guertel 18-20, 1090 Vienna, Austria Department of Obstetrics and Gynecology, Medical University of Vienna, Vienna, Austria

# Chapter 1

## The History of the Myelodysplastic Syndromes

Ray M. Lowenthal

The conditions that now come under the rubric of the myelodysplastic syndromes (MDS) have been recognised for over a century under a variety of names. Indeed, few haematological conditions seem to have excited as much interest in their history. Every review of MDS, it seems, is accompanied by a historical overview. So, how to provide information that is different? Where to begin? Perhaps we should look earlier than the first possible description of the disorder.

The portrayal of MDS as an entity has relied on many preceding breakthroughs in the development of the speciality of haematology. One of the first was the recognition of the bone marrow as being the site of blood formation, a discovery attributed to Ernst Neumann (1834–1918) [1, 2]. The first comprehensive description of the various blood cells and their morphology was given by the German scientist/physician Paul Ehrlich (1854–1915) in 1879 [3]. Ehrlich as a young man developed staining techniques which allowed the ‘colourless’ corpuscles (the leucocytes) to be visualised. This he achieved by utilising aniline dyes which contemporaneously were being developed by the German chemical industry for textile manufacturers [4]. Amongst other things he was the first to describe aplastic anaemia and distinguish it from other forms of anaemia. Ehrlich himself relied on developments in microscopy which took place over several centuries [5], and include particularly the name of Antonj van Leeuwenhoek (1632–1723).

Another early discovery that has relevance to the MDS story was made in 1898. It was in that year that Marie and Pierre Curie described the element radium and its radioactivity, a discovery which in turn led to the development of radiotherapy. In the early part of the twentieth century radiotherapy was commonly used to treat the splenomegaly of some types of leukaemia and presumably also MDS; an irony, given that we now know that ionising radiation itself can cause leukaemia and MDS [6]. Indeed both Marie Curie and her elder daughter Irène, who carried on her

---

R. M. Lowenthal (✉)

Department of Clinical Haematology and Medical Oncology and Menzies Research Institute  
Tasmania, Royal Hobart Hospital, Hobart, TAS, Australia

Tel.: +61-3-6222-8157

Fax: +61-3-6226-4894

e-mail: r.m.lowenthal@utas.edu.au

mother's work on radioactivity after her mother's death, are said to have died of 'leukaemia'. Even more ironically Marie's final illness, as reported in the biography written by her younger daughter Eve, could well be interpreted as MDS, particularly as she is said to have been anaemic for years beforehand. According to Eve, quoting the physician who cared for her, Marie died of 'aplastic pernicious anaemia of rapid, feverish development. The bone marrow did not react' [7].

Layton and Mufti (1986) provide a comprehensive bibliography of the important advances in the history of MDS up to that time [8]. They claim that the first account of MDS can be attributed to von Leube in 1900 who described a case of megaloblastic anaemia which preceded the onset of leukaemia [9].

Early appellations for the conditions which now come under the heading of MDS included *pseudo-aplastic anaemia* [10], a term that was based on the presence of peripheral blood cytopenias with a cellular rather than aplastic marrow; and *refractory anaemia* [11] on the grounds of the patient having a form of anaemia that did not respond (was 'refractory') to the known haematinics, iron, folic acid and vitamin B12 [12]. The first winner of the Harvey Cushing prize for the best essay on a topic in medical history was Jean Captain Sabine, who in 1938, wrote "A History of the Classification of Human Blood Corpuscles." In it he summarised all the work up to that point [13].

In 1942 Chevallier and colleagues described a case they called *odo-leukemia*, odo allegedly being Greek for 'threshold' (indicating the condition being on the threshold of—or almost—leukaemia [14]. Interestingly they attributed their case to excessive exposure to benzene. In the late 1940s it was recognised that some cases of peripheral blood cytopenias ultimately transformed into acute leukaemia (usually of the myeloid type), thus leading to the terms *preleukaemia* or *preleukaemic anaemia* [15]. Then in the 1950s came the appreciation that cases of 'refractory' leucopenia or thrombocytopenia had a similar significance to refractory anaemia; this led to broadening of the terminology to include *refractory cytopenia* [16]. Further study of the natural history of the refractory cytopenias showed that they by no means all transformed to leukaemia, indeed only a minority did so, leading to the appreciation that the term 'preleukaemia' was prognostically misleading and that an alternative term was needed. Other early terms used (before 1976) included *sideroblastic anaemia* [17], *smouldering leukaemia* [18, 19] and *dysmyelopoietic anaemia*—this latter term continues to have currency [20]. The term *subacute myeloid leukaemia* probably refers to a subset of MDS [21].

The first FAB classification of the leukaemias, which included MDS, was proposed in 1976 [22] and a revision which expanded the system as it applied to MDS was introduced in 1982 [23]. The initial WHO classification was developed in 2000 [24] and revised in 2008 [25, 26].

Highlights in the scientific understanding of MDS include the first verification of the clonality of the condition, by G6PD isoenzyme studies [27] and the discovery of cytogenetic abnormalities including 5q- [28, 29].

In 1997 Greenberg et al. introduced an international prognostic scoring system (IPSS) [30] that has become widely used; it was created in an attempt to synthesise information from several previously used scoring systems including those devised in Bournemouth, UK [31], Valencia, Spain [32], and Dusseldorf, Germany [33].

The history of the treatment of MDS is unfortunately much shorter and less satisfactory than the history of its discovery and biology. Highlights include the use of bone marrow transplantation [34], the first report of use of growth factors, with GM-CSF [35]; the introduction of azacytidine, the first demethylating agent brought into clinical practice [36]; and the use of lenalidomide [37].

Hopefully when the history of the myelodysplastic syndromes is re-written in decades hence, much more will be said about the success of treatments.

## References

1. Neumann E (1869) Über die Bedeutung des Knochenmarkes für die Blutbildung. ein Beitrag zur Entwicklungsgeschichte der Blutkörperchen. Arch Heilkd 10:68–102
2. Tavassoli M (1980) Bone marrow: the seedbed of blood. In: Wintrobe MM (ed) Blood, pure and eloquent. McGraw-Hill, New York, pp 57–79
3. Ehrlich P (1879) Methodologische Beiträge zur Physiologie und Pathologie der verschiedenen Formen der Leukocyten. Z Klin Med 1:553–560
4. Ehrlich P (1877) Beitrag zur Kenntnis der Anilinfärbungen und ihrer Verwendung in der mikroskopischen. Technik Arch Mikr Anat 13:263–277
5. Wintrobe MM (1980) Blood, pure and eloquent. McGraw-Hill, New York
6. Matsuo T, Tomonaga M, Bennett JM, Kuriyama K, Imanaka F, Kuramoto A, Kamada N, Ichimaru M, Finch SC, Pisciotto AV et al (1988) Reclassification of leukemia among A-bomb survivors in Nagasaki using French-American-British (FAB) classification for acute leukemia. Jpn J Clin Oncol 18:91–96
7. Curie E (1937) Madame Curie. Doubleday, Garden City
8. Layton DM, Mufti GJ (1986) Myelodysplastic syndromes: their history, evolution and relation to acute myeloid leukaemia. Blut 53:423–436
9. von Leube W (1900) Rapid verlaufende schwere Anämie mit gleichzeitiger leukämischer Veränderung des Blutbildes. Klin Wochenschr 37:85–97
10. Luzzatto AM (1907) Sull anemia grave megiloblastica sensa reporto ematologica corrispondente (anemia pseudoaplastica). Riv Veneta Med Venezia 47:193
11. Rhoades CP, Barker WH (1938) Refractory anemia: an analysis of one hundred cases. J Am Med Assoc 110:794–796
12. Bomford RR, Rhodes CP (1941) Refractory anemia. Q J Med 10:175–281
13. Sabine JC (1940) A history of the classification of human blood corpuscles. Bull Hist Med 8:696–720, 785–805
14. Chevallier P, LaMotte M, Umdenstock R (1942) Trois cas d’anémie-leucose benzolique. Le Sang 15:391–405
15. Hamilton-Paterson JL (1949) Preleukemia anemia. Acta Hematol 2:309–316
16. Block M, Jacobson LO, Bethard WF (1953) Preleukemic acute human leukaemia. J Am Med Assoc 152:1018–1028
17. Björkman SE (1956) Chronic refractory anemia with sideroblastic bone marrow; a study of four cases. Blood 11:250–259
18. Rheingold JJ (1974) Acute leukemia. Its smoldering phase, or leukemia never starts on thursday. J Am Med Assoc 230:985–986
19. Rheingold JJ, Kaufman R, Adelson E, Lear A (1963) Smoldering acute leukemia. N Engl J Med 268:812–815
20. Rosenthal DS, Moloney WC (1984) Refractory dysmyelopoietic anemia and acute leukemia. Blood 63:314–318

21. Cohen JR, Creger WP, Greenberg PL, Schrier SL (1979) Subacute myeloid leukemia: a clinical review. *Am J Med* 66:959–966
22. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C (1976) Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. *Br J Haematol* 33:451–458
23. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C (1982) Proposals for the classification of the myelodysplastic syndromes. *Br J Haematol* 51:189–199
24. Bennett JM (2000) World Health Organization classification of the acute leukemias and myelodysplastic syndrome. *Int J Hematol* 72:131–133
25. Swerdlow S, Campo E, Harris NL, Jaffe ES, Pileri S, Stein H, Thiele J, Vardiman JW (eds) (2008) WHO classification of tumours of the haematopoietic and lymphoid tissues. IARC, Lyon
26. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellstrom-Lindberg E, Tefferi A, Bloomfield CD (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. *Blood* 114:937–951
27. Raskind WH, Tirumali N, Jacobson R, Singer J, Fialkow PJ (1984) Evidence for a multistep pathogenesis of a myelodysplastic syndrome. *Blood* 63:1318–1323
28. Van den Berghe H, Cassiman JJ, David G, Fryns JP, Michaux JL, Sokal G (1974) Distinct haematological disorder with deletion of long arm of no. 5 chromosome. *Nature* 251:437–438
29. Haase D (2008) Cytogenetic features in myelodysplastic syndromes. *Ann Hematol* 87:515–526
30. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. *Blood* 89:2079–2088
31. Mufti GJ, Stevens JR, Oscier DG, Hamblin TJ, Machin D (1985) Myelodysplastic syndromes: a scoring system with prognostic significance. *Br J Haematol* 59:425–433
32. Sanz GF, Sanz MA, Vallespi T, Canizo MC, Torrabadella M, Garcia S, Irriguiñe D, San Miguel JF (1989) Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. *Blood* 74:395–408
33. Aul C, Gattermann N, Heyll A, Germing U, Derigs G, Schneider W (1992) Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. *Leukemia* 6:52–59
34. Tallman MS, McGuffin RW, Higano CS, Starkebaum G, Collins SJ, Johnston H, Singer JW, Perry DJ, Kunath A (1987) Bone marrow transplantation in a patient with myelodysplasia associated with diffuse eosinophilic fasciitis. *Am J Hematol* 24:93–99
35. Vadhan-Raj S, Keating M, LeMaistre A, Hittelman WN, McCreddie K, Trujillo JM, Broxmeyer HE, Henney C, Gutterman JU (1987) Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. *N Engl J Med* 317:1545–1552
36. Chitambar CR, Libnoch JA, Matthaeus WG, Ash RC, Ritch PS, Anderson T (1991) Evaluation of continuous infusion low-dose 5-azacytidine in the treatment of myelodysplastic syndromes. *Am J Hematol* 37:100–104
37. List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D, Rimsza L, Heaton R, Knight R, Zeldis JB (2005) Efficacy of lenalidomide in myelodysplastic syndromes. *N Engl J Med* 352:549–557



## Chapter 2

# Susceptibility to MDS: DNA Repair and Detoxification Genes

Claire Seedhouse and Nigel Russell

### Introduction

The myelodysplastic syndromes (MDS) are a collection of heterogeneous disorders arising from a clonal myeloid stem cell. They are characterised by ineffective haematopoiesis and are frequently associated with genetic instability manifested as chromosomal abnormalities. MDS progresses through a pathway of one or more dysplasias and ends in myeloid leukaemia—the risk of developing acute myeloid leukaemia (AML) depends on the subtype of MDS. Similar to other malignant diseases, the stepwise disease progression is likely to be the consequence of the accumulation of mutations, probably due to an increased DNA damage burden and/or reduced ability to deal with the damage.

MDS risk has previously been associated with benzene exposure or exposure to a number of other environmental toxins. In addition a subset of patients develop the disease following chemotherapy or radiotherapy treatment for a primary disease (therapy-related MDS (t-MDS)). Mammalian cells have a number of efficient systems designed to metabolise and inactivate harmful genotoxic agents, or if the agents manage to induce damage then complex DNA repair mechanisms effectively remove the damage. Importantly, if the damage is excessive, DNA damage response proteins will trigger the apoptotic pathway to get rid of the cell for the good of the whole organism. These systems are not only required for protection from exogenous damaging agents but also for the constant damage cells receive from endogenous cellular processes, predominantly oxidative stress.

MDS incidence increases with increasing age suggesting that the genotoxic burden on DNA eventually reaches a critical level resulting in disease. What, however, predisposes some individuals to the development of MDS when they have encountered a similar level of damage as an individual who remains healthy? A large body

---

C. Seedhouse (✉)

Department of Academic Haematology, University of Nottingham, Clinical Sciences Building, Nottingham University Hospitals—City Campus, NG5 1PB Nottingham, UK

Tel.: +44-115-8231822

Fax: +44-115-8231820

e-mail: [claire.seedhouse@nottingham.ac.uk](mailto:claire.seedhouse@nottingham.ac.uk)

of research suggests that the answer, at least in part, is genetic variation in key genes involved in (1) protection of cellular entities from damage and (2) repair of DNA damage. Mutations in these genes are rare but of high penetrance and lead to serious genetic diseases; one example of a disease arising from mutations in DNA repair genes is Fanconi Anaemia which carries a strong predisposition to MDS. Much more common are genetic polymorphisms that occur in many of the genes which function to protect our genomes. This chapter aims to summarise research published on polymorphisms in detoxification and DNA repair genes in MDS. Therapy-related MDS is rarely investigated alone but is commonly grouped with therapy-related AML and indeed t-AML and t-MDS are now classified together by the World Health Organisation. There is a great deal of research that has been done on polymorphisms in t-AML/MDS (reviewed in Seedhouse and Russell [67]), so we will concentrate on work performed on de novo MDS samples and only positive associations of polymorphisms with t-AML/MDS will be discussed.

## Detoxification Pathways

The first line of defence to genotoxic agents is detoxification—this should occur before the agents are able to damage cellular molecules. Metabolism of endogenous and exogenous agents occurs by the same pathways and is divided into two phases. Phase I involves activation of substrates into electrophilic intermediates; these reactions are predominantly catalysed by the cytochrome P450 (CYP) protein family, many of which harbour polymorphisms which affect their function. The products of the phase I reactions are highly reactive and liable to cause severe cellular damage and the phase II enzymes (conjugation) are required to inactivate the phase I products. Enzymes that participate in phase II include the glutathione S-transferases (GST) and NAD(P)H:quinine oxidoreductase-1 (NQO1). These enzymes not only detoxify reactive phase I products but also act on genotoxic agents that do not require phase I activation.

The balance of phase I and II activity is critical and a consequence of high levels of phase I activity with low levels of phase II activity is the production of deleterious metabolites which will damage cell components, especially DNA. It follows that polymorphisms affecting the function of either phase I or II proteins, or indeed proteins from both phases, may upset the balance of detoxification activity and predispose individuals to high levels of damaging agents.

### *Phase I: Cytochrome P450 Enzymes*

The cytochrome P450 superfamily comprises a large and diverse group of membrane-associated haem-proteins divided into 18 families. They are responsible for the metabolism of both endogenous and exogenous substrates, largely via an oxidative reaction, creating highly reactive intermediates that cause damage to DNA

unless detoxified by phase II proteins (reviewed in Nebert and Dalton [53]). The CYP proteins can be induced or inhibited resulting in highly variable expression. In addition polymorphisms exist in many of the family members which affect the function of the protein and contribute to high inter-individual variability. The allele frequencies of several of the polymorphic variants have been examined as potential disease risk-factors in MDS populations.

### **CYP2E1**

CYP2E1 harbours a C to T single nucleotide polymorphism (SNP) in its 5' promoter (CYP2E1\*5) which is associated with increased transcriptional activity [30]. CYP2E1 is known to play an important role in the metabolism of benzene, exposure to which is a known risk factor to MDS. The CYP2E1\*5B polymorphism has been studied to establish whether the variant allele increases susceptibility to benzene poisoning and hence MDS but no association was found [64].

### **CYP3A4**

An A to G SNP is present in the CYP3A4 5' promoter (CYP3A4\*1B). The variant was initially proposed to alter a regulatory element within the promoter with a resulting decrease in activity [63]. Conversely, further biological assays failed to demonstrate specific functional differences between the variant and wild-type alleles [76, 85]. Fabiani et al. found no risk for MDS associated with CYP3A4\*1B [23].

### **CYP3A5**

Two SNPs exist within CYP3A5 (CYP3A5\*3 and CYP3A5\*6) both of which cause alternative splicing and truncated proteins resulting in the absence of CYP3A5 [40]. The frequencies of these polymorphisms have been studied in a Taiwanese MDS population. There was no difference in the distribution of the CYP3A5\*3 allele in MDS when compared to a healthy control cohort and the CYP3A5\*6 allele was not found in cases or controls [46].

### **Significant Findings of CYP Variants in t-AML/MDS**

A large number of studies have been published examining the distribution of several of the CYP variant alleles in t-AML/MDS (reviewed in Seedhouse and Russell [67]). However, the only significant findings have been concerning the CYP3A4 A to G 5' promoter polymorphism. The polymorphic variant (CYP3A4\*1B) was found to be under-represented in a group of 30 childhood t-MDS/leukaemia samples when compared to a control group of paediatric patients with de novo leukaemia (odds ratio (OR) 0.09; 95% confidence intervals (CI) 0.01–0.87) [24] suggesting that the

variant allele may result in a decrease in DNA-damaging reactive intermediates and therefore protect against t-AML/MDS. These results were corroborated by Rund et al. [65] when comparing healthy controls with adult t-AML/MDS patients.

## ***Phase II: Glutathione S-transferases***

The glutathione S-transferase (GST) multigene family is a major class of phase II detoxification enzymes. Their substrates are manifold and include environmental mutagens, drugs and products of oxidative stress which may, or may not, be by-products of a phase I reaction. The mode of action of the GSTs is conjugation of the reactive electrophilic substrates to glutathione. There are at least four cytosolic GST subfamilies: alpha (A), mu (M), pi (P) and theta (T) and functionally relevant polymorphisms exist in each subfamily.

### **GSTM1 and GSTT1**

GSTM1 and GSTT1 have attracted considerable interest because both genes are commonly deleted [61, 70]. The homozygous deletion GSTM1 polymorphism exists in approximately 50% of Caucasians and the GSTT1 deletion in 25%; these frequencies differ between races. Most studies examining the cellular consequences of the GSTM1 or GSTT1 deletions point towards reduced detoxification activity resulting in higher levels of DNA damage [15, 32, 73, 86, 87]. A large number of studies have examined the importance of the GSTM1 and GSTT1 deletions in MDS (summarised in Table 2.1) with some finding positive associations for either GSTM1 null, or GSTT1 null, or for the combined GSTM1 and GSTT1 null genotypes with MDS.

Dahabreh et al. have performed a meta-analysis of GSTM1 and GSTT1 deletion polymorphisms in MDS [20]. They identified 13 eligible studies for GSTT1 comprising a total of 1,471 cases and 1,907 controls. Using both fixed and random effects models the GSTT1 null genotype was shown to be significantly associated with an increased risk of MDS (Fixed effects OR 1.44, 95% CI 1.21–1.72,  $p < 0.0001$ ; random effects OR 1.43, 95% CI 1.09–1.89,  $p = 0.01$ ). This study provides strong evidence that the GSTT1 null genotype is associated with MDS susceptibility. For GSTM1, ten eligible studies were identified totalling 1,161 cases and 1,668 controls. Neither the fixed or random effects models showed an association between GSTM1 null and MDS.

When MDS patients are divided into further sub-groups the majority of studies have shown a trend for the GSTT1 null genotype being more prevalent in the RA/RARS FAB subtypes than the more aggressive RAEB/RAEB-T subtypes; however no study has reached statistical significance. Within the subgroup analyses one paper of particular interest is by Stavropoulou et al. [77] who studied a large series of well characterised MDS patients ( $n = 323$ ) enabling analysis of genotype

**Table 2.1** Summary of de novo MDS studies on *GSTM1* and *GSTT1* polymorphisms

	Control population	MDS deletion frequency (%)	Control deletion frequency (%)	OR (95% CI)	Reference
<i>GSTM1</i> deletion					
92 MDS	201 cancer-free, similar age, sex and race	42	48	0.8 (0.5–1.3)	[16]
166 MDS	112 haematologically normal staff and patients	55	48	0.89 (0.5–1.43)	[7]
116 MDS	43 healthy volunteers	55	53	0.80 (0.62–2.43)	[66]
54 MDS	60 cancer-free, matched for age and sex	57.4	33.3	2.70, p < 0.01	[80]
49 MDS	102 newborn	36.7	36.9	0.9 (0.5–1.9)	[6]
128 MDS	239 healthy, similar sex and race	53	51	Not given, non-significant	[27]
73 MDS <sup>a</sup>	Gaete et al. <sup>b</sup> [26]	70	52	2.32, p = 0.002	[78]
302 MDS	330 healthy, matched for age and sex	35.4	42.4	p = 0.086	[77]
86 MDS	99 hospitalised controls, matched for age and sex	47.7	48.5	Not given, non-significant	[81]
157 MDS	155 cancer-free, matched for age and sex	51.6	59.4	0.73 (0.45–1.17), p = 0.2	[23]
<i>GSTT1</i> deletion					
92 MDS	190 cancer-free, similar age, sex and race	46	16	4.3 (2.5–7.4)	[16]
166 MDS	112 haematologically normal staff and patients	21	16	0.72 (0.4–1.34)	[7]
57 MDS	100 haematologically normal staff and patients	28	23	Not given, non-significant	[9]
59 MDS	50 normal controls	46	46	Not given, non-significant	[59]
158 MDS	100 blood donors, similar age and sex	21	19	Not given, non-significant	[62]
116 MDS	43 healthy volunteers	53	30	2.65 (1.27–5.52) p < 0.01	[66]
54 MDS	60 cancer-free, matched for age and sex	11.1	6.66	1.75, not significant	[80]
49 MDS	102 newborn	14.2	18.1	0.7 (0.2–1.8)	[6]
128 MDS	239 healthy, similar sex and race	22	16	Not given, non-significant	[27]
73 MDS <sup>a</sup>	Gaete et al. <sup>b</sup> [26]	36	15	1.81, p < 0.001	[78]
323 MDS	330 healthy, matched for age and sex	17.9	15.8	p = 0.518	[77]
86 MDS	99 hospitalised controls, matched for age and sex	19.8	25.3	Not given, non-significant	[81]
156 MDS	155 cancer-free, matched for age and sex	24.4	18.1	1.46 (0.82–2.62), p = 0.22	[23]
<i>Combined GSTM1 and GSTT1 deletions</i>					
49 MDS	102 newborn	6.1	10.8	1.2 (0.2–4.7)	[6]
128 MDS	239 healthy, similar sex and race	7.8	8.8	Not given, non-significant	[27]
86 MDS	99 hospitalised controls, matched for age and sex	5.8	13.1	Not given, non-significant	[81]
73 MDS <sup>a</sup>	Gaete et al. <sup>b</sup> [26]	26	7	2.86, p < 0.001	[78]
116 MDS	43 healthy volunteers	33	21	1.84 (0.81–4.19)	[66]
54 MDS	60 cancer-free, matched for age and sex	3	0	–	[80]
294 MDS	330 healthy, matched for age and sex	6.8	6.1	p = 0.830	[77]

Studies showing significant associations with MDS are shaded

<sup>a</sup>Only Caucasian results shown, other racial groups had very low numbers (n < 10)

<sup>b</sup>Published gene frequencies of healthy human subjects sorted by race (n > 15000)

frequencies within specific cytogenetic groups. They discovered that none of the five patient samples with an isolated 5q deletion were GSTT1-null and also noted that, in a previous publication, there were 0/10 del5q patients who had a GSTT1 null genotype [62]. By increasing their data set to 47 samples (22 of which had an isolated 5q-, 4 a 5q- with one additional abnormality and 21 a -5/del5q as part of a complex karyotype) Stavropoulou et al. found only two samples with a GSTT1 null genotype. This was highly significant when comparing to MDS samples with other karyotypic abnormalities or to the normal controls. These striking findings were explained by the fact that exposure to organic solvents had previously been associated with chromosome 5q abnormalities and that GSTT1 enzyme activity is required for some organic solvents to form mutagenic metabolites. Hence Stavropoulou et al. hypothesised that the presence of the GSTT1 gene is not always protective but may confer MDS risk following particular chemical exposure by promoting specific genetic damage.

### **GSTP1 and GSTPA1**

The third polymorphic GST which has been widely studied in disease-risk is GSTP1. This gene has a G to A SNP which results in an ile to val amino acid change at codon 105 of the protein [1]. Codon 105 resides in the electrophile-binding site of the GSTP1 protein and the altered properties of the val amino acid affects both the catalytic activity of the enzyme, in a substrate-dependent manner, and its thermal stability.

Two studies have been published examining the contribution of the GSTP1-105 polymorphism to de novo MDS risk, the first found no positive association [66], whilst Fabiani et al. in the latter study found an increased risk of MDS associated with the presence of at least one variant val allele (OR1.66, 95% CI 1.03–2.67;  $p=0.04$ ) [23]. Furthermore patients with low/intermediate risk MDS (IPSS risk group low/intermediate-1) had a higher probability of overall survival if they harboured a GSTP1-105 val allele ( $p=0.008$ ). Fabiani and colleagues also examined the GSTPA1-C69T promoter variant in their study. This polymorphism has been shown to be correlated with GSTA1 expression [19]. There was no association between the GSTP1A-69T variant and MDS risk.

### **Significant Findings of GST Polymorphisms in t-AML/AML**

A comprehensive summary of GST polymorphisms in t-AML/MDS can be found in Seedhouse and Russell [67]. Two studies demonstrated significant associations between the GSTT1 null polymorphism and t-AML/MDS disease incidence [2, 66]. In addition Allan et al. showed that individuals with at least one GSTP-105Val allele were significantly over-represented in t-AML/MDS when compared with either a control or a de novo AML group. The odds ratio was increased if only those patients

who had received chemotherapy were considered and further increased in the subgroup of patients who had prior exposure to a known GSTP1 substrate. Subgroup analysis by Haase et al. [27] also provided interesting results with a highly significant increase in the risk of developing t-MDS/AML following breast cancer treatment when the double GSTM1/GSTT1 null genotype was present. This was further pronounced when considering patients who had been treated with chemotherapy for their breast cancer.

### **NAD(P)H: Quinone Oxidoreductase (NQO1)**

NQO1 uses NADH or NADPH to catalyse 2- or 4-electron reductions of its quinone substrates thereby producing less reactive hydroquinones. This activity plays a critical role in detoxification preventing the generation of ROS and free-radicals that would otherwise go on to damage DNA and other cellular components. The NQO1 gene has a well studied C to T SNP at position 609 resulting in a pro to ser amino acid substitution at codon 187 [79]. The variant ser-containing protein has negligible enzymatic activity and is no longer inducible in bone marrow cells following benzene metabolite exposure. An allele dosage effect occurs with the ser/ser homozygote having no activity and the pro/ser heterozygote showing intermediate activity between the homozygote variant and wild type proteins [51, 74]. Benzene poisoning is associated with a very strong risk of MDS development and the NQO1 serine allele increases the risk of benzene poisoning [64], there has therefore been interest in the distribution of the NQO1 polymorphism in MDS. Whilst no relationship has been found between the NQO1 SNP and de novo MDS risk [23, 43], these results are contrary to findings from several studies on the therapy-related disease (see below).

### **Significant Findings of NQO1-Pro187Ser in t-AML/MDS**

Larson et al. found a significant over-representation of the NQO1-187ser allele in a t-AML/MDS cohort: interestingly 7/8 of the ser/ser homozygotes had abnormalities of either chromosome 5 and/or 7 [43]. Naoe et al. [52] confirmed these findings in 58 t-AML/MDS patients with the ser variant homozygous genotype conferring an odds ratio of 2.62 (95% CI 2.16–3.08) although chromosome 5 and/or 7 abnormalities were not over-represented in their variant homozygote samples.

## **DNA Repair**

Cells encounter constant attack from molecules which can damage DNA. Efficient detoxification mechanisms limit cellular damage but, even so, DNA cannot be entirely spared and therefore complex pathways are present to repair DNA damage

and minimise its deleterious effects. The balance of DNA repair is critical—whilst too little repair can result in the acquisition and persistence of mutations and genetic instability, too much repair can be equally harmful by inhibiting the apoptotic pathway and enabling a cell with badly damaged DNA to attempt repair, possibly mis-repair and survive. DNA damage is known to accumulate with age and eventually overloads the repair systems leading to haematopoietic stem cell (HSC) exhaustion. A number of studies using mouse models have effectively demonstrated the importance of DNA repair genes, involved in a number of different repair pathways, in maintaining HSC function (reviewed in Niedernhofer [55]).

MDS is primarily a disease of the elderly and some cases can occur following large genotoxic insults such as chemotherapy drug treatment. If the damage levels sustained with increasing age or genotoxic insult are unrepaired and reach a certain threshold, protective cell senescence or apoptosis should be triggered. If these mechanisms fail then the genomic instability may prime stem cells for further mutation development and functional cellular abnormalities ultimately resulting in MDS and/or leukaemia.

There is a significant body of research demonstrating high levels of DNA damage in MDS samples. Increased levels of the major oxidative damage product, 7,8-dihydro-8-oxoguanine (8-oxoG), have been found in MDS patient bone marrow samples when compared to normal bone marrow controls [33] and increased levels of oxidised pyrimidine nucleotides are seen in CD34+ enriched MDS bone marrow samples compared to either CD34- MDS samples or CD34+ bone marrow cells from normal subjects [60]. Novotna et al. have also shown higher levels of oxidative damage and genetic instability in samples from MDS patients when compared to age matched controls [56, 57]. It is not clear whether the increased DNA damage is a cause, or a result, of the MDS disease. Whilst genetic instability is one of the main prerequisites for disease development, once the disease is established iron overload in transfusion-dependent patients and reactive oxygen species generation from inflammation also have to be considered among important factors in determining the burden of DNA damage. Whatever the case, the additional DNA damage burden means that aberrant activities of DNA repair genes are likely to be particularly important in MDS.

### ***Double Strand Break Repair***

DNA double strand breaks (DSBs) are the most important class of DNA damage because, if unrepaired, they can result in a loss of genetic material, chromosome abnormalities and possibly cell death. The two major mechanisms that repair DSBs are the homologous recombination and non-homologous end-joining pathways.

#### **Non-homologous End Joining**

Non homologous end joining (NHEJ) is active in all phases of the cell cycle and is considered to be the most important DSB repair pathway in mammalian cells. In



NHEJ the DSB is recognised by the Ku70/Ku80 heterodimer which then forms a complex with DNA-PKcs. Following recruitment of further proteins and DNA end processing, a XRCC4-ligase IV complex re-ligates the break. A number of patients have been reported who have a mutation in the ligase IV gene—Ligase IV syndrome—and bone marrow abnormalities, including MDS, are amongst the many clinical disorders (reviewed in Chistiakov et al. [17]).

Polymorphisms in NHEJ genes have been identified but have not been studied in either de novo MDS or t-AML/MDS. However a recent study found differences in the expression of several of the NHEJ proteins in MDS samples [22]. Expression of ligase 4 was significantly elevated in MDS bone marrow samples compared to control bone marrow with the high expression appearing to be associated with a good risk karyotype. Conversely, the Ku70 protein levels were significantly lower in patients with a good risk karyotype.

## Homologous Recombination

Homologous recombination (HR) repair is a tightly regulated, high-fidelity process. It uses a second, intact copy of the chromosome as a template to copy the information lost at the DSB site. A number of polymorphic genes involved in the pathway have been studied in the context of MDS.

### RAD51 and XRCC3

RAD51 is a central protein in the HR repair pathway binding to DNA and promoting ATP-dependent homologous pairing and strand transfer reactions. XRCC3 also participates in the pathway interacting with, and stabilising, RAD51. Polymorphisms are present in the RAD51 and XRCC3 genes.

RAD51 has a G to C polymorphism at position -135 of the 5' promoter of the gene [83]. Characterisation of the RAD51 promoter demonstrated that the -135 variant C allele was associated with increased promoter activity [29]. However, a further study suggested that the effect of the polymorphism was due to alternative splicing within the RAD51 5'-untranslated region [4]. The substitution of C for G abolishes a splice site resulting in low transcript levels of the longer RAD51 isoform (isoform 2). The authors suggested that as isoform 2 lacks a translation-inhibitory GC-rich region then it would be expected to have increased translation efficiency. As the polymorphic variant results in less isoform 2, subsequently, a reduction in RAD51 protein may occur.

The XRCC3 gene is also polymorphic and a thr to met substitution occurs at codon 241 [72]. Whilst the variant protein has been shown to complement the DNA repair defect in a XRCC3-deficient cell line [5], further work determined that the variant protein was unable to apoptotically eliminate aberrant cells with mitotic defects resulting in genetic instability [45].

Two studies have found no differences in the distribution of the RAD51-G135C and XRCC3-thr241met polymorphisms in MDS samples compared to controls

[10, 23]. Baumann et al. also found no difference if the two polymorphisms were analysed in combination. In t-AML/MDS we found an over-representation of the RAD51-135C allele when compared with a control group (OR 2.66, 95% CI 1.17–6.02,  $p=0.02$ ) [69]. Whilst there was no difference in the distribution of the XRCC3 polymorphism, when we looked at the combination of variant RAD51 and XRCC3 alleles we found a prominent synergistic effect resulting in an odds ratio of more than 8 (OR 8.11, 95% CI 2.22–29.68,  $p=0.002$ ).

### BLM, TOP3A and RMI1

Bloom syndrome is a rare autosomal recessive disorder characterised by growth retardation, sensitivity to light and a predisposition to the development of many cancers including leukaemia and MDS. BLM is a RecQ helicase which prevents illegitimate recombination in mitotic cells. The BLM gene is mutated in Bloom syndrome resulting in an elevated frequency of exchange between homologous chromosomes and sister chromatids. BLM interacts physically and functionally with both topoisomerase IIIa (TOP3A) and RMI1/BLAP75 (reviewed in [75]). Polymorphisms in BLM, RMI1 and TOP3A have been studied in MDS.

RMI1 harbours a G to A polymorphism which results in a ser to asn change at codon 455 of the protein. Ser455 is evolutionarily conserved however the functional consequences of the polymorphism are unknown [13]. The presence of the polymorphic asn residue was demonstrated to be a risk factor for MDS (OR 1.9, 95% CI 1.1–3.3) [13]. Interestingly the effect was stronger in those patients over the age of 65 years which the authors suggested may reflect the fact that mitotic recombination increases with age and aberrations of proteins involved in this process may therefore be expected to have an increased influence as mitotic recombination increases. A second study by the same group examined a further 26 polymorphisms in RMI1, BLM and TOP3A in a mixed group of MDS and AML samples (37% MDS; 12% AML secondary to MDS; 51% AML). Of particular attention when analysed singly were TOP3A GA rs12945597 where the homozygous variant was associated with a 4.6-fold increase risk of MDS/AML (95% CI 1.7–14) and BLM AC rs6496724 for which the variant homozygote was less frequent in MDS/AML (OR 0.34, 95% CI 0.12–0.95) [14]. Following analyses of multiple myeloma, bladder and breast cancer samples in addition to the MDS/AML cohort, combinations of polymorphisms were chosen. The TOP3A rs12945597 A allele in combination with the BLM rs2532105 variant T allele resulted in an odds ratio of 2.4 for MDS/AML risk (95% CI 1.1–5.4). None of the functional effects of the polymorphisms, if any, are known.

### ***Base Excision Repair: hOGG1***

The base excision repair (BER) pathway corrects individually damaged bases which can occur via a number of different mechanisms but predominantly via

oxidation. The major product of oxidative damage to DNA is 8-oxoG. 8-oxoG is highly mutagenic as it has a tendency to mispair with adenine thereby generating GC to TA transversions. The human glycosylase responsible for repairing this base adduct is hOGG1 (reviewed in Klungland and Bjelland [36]). A SNP exists at position 1,245 of the hOGG1 gene resulting in a ser to cys amino acid change at codon 326 in exon 7 of the corresponding protein. The cys-encoding protein has been shown to have a reduction in its repair activity compared to the wild type ser protein [38]. Jankowska et al. have provided a comprehensive analysis of the importance of 8-oxoG in MDS including the genotyping of 146 MDS patients for the hOGG1 ser326cys polymorphism [33]. When comparing the distribution of the hOGG1 SNP in MDS to that of a cohort of 350 controls, significantly increased risks for MDS were found for both heterozygote (OR 1.7, 95% CI 1.1–2.5,  $p=0.02$ ) and homozygote cases (OR 2.8, 95% CI 1–7.2,  $p=0.05$ ). The cys allele was associated with conferring a particularly strong risk for advanced MDS and additionally there was a significant positive relationship between the presence of the cys allele and the frequency of chromosomal abnormalities ( $p<0.02$ ). The authors also compared hOGG1 mRNA expression between the different hOGG1 genotype groups with the carriers of hOGG1-cys326 exhibiting significantly higher hOGG1 levels when compared to the wild type hOGG1 ser/ser cases ( $p=0.008$ ). They suggested that this could be due to a feedback mechanism attempting to compensate for the reduced activity of the cys allele.

XRCC1 also participates in the BER pathway acting as a scaffold and recruiting other BER proteins to the repair site. A common variation in the gene substitutes arg for met at position 399 of the protein, a region which comprises the BRCT domain [72]. The variant Gln residue has been shown to result in significant conformational changes to the XRCC1 protein [50] and a large number of studies have shown that cells harbouring the variant gln allele have a decreased capacity to repair DNA damage resulting in increased DNA damage levels [8, 21, 41, 44, 47, 82, 84]. We have demonstrated that the presence of a variant XRCC1-399 gln allele was actually protective for t-AML/MDS (OR 0.44, 95% CI 0.20–0.93,  $p=0.03$ ) [68]. We consider this result indicates a strong gene-environmental interaction. The genotoxic therapy a patient receives for their primary condition is likely to cause very high DNA damage levels in some HSCs. Cells with reduced BER capacity, that is a XRCC1-399gln allele, are more likely to be driven towards apoptosis whilst the wild type cells may attempt repair but misrepair resulting in mutations and a clone which can initiate t-AML/MDS. This gene-environment (XRCC1-399gln: high DNA damage) hypothesis is supported by a study of XRCC1-399gln in non-melanoma skin cancer which is also associated with high levels of DNA damage; similar to t-AML/MDS a protective effect of the gln allele was found [54]. Furthermore in a meta-analysis of XRCC1-399 in smoking-related cancers, the variant gln allele was found to confer an increased risk in light smokers, but was protective among heavy smokers who presumably have high levels of DNA damage [31].

## ***Nucleotide Excision Repair***

Whereas BER removes the products of minor structural base damages, nucleotide excision repair (NER) removes bulky damages which distort the DNA helix. The NER repair pathway consists of removing segments of ssDNA containing the bulky lesion followed by repair synthesis by a DNA polymerase and ligation. Kuramoto et al. measured the mRNA expression levels of several genes involved in the NER pathway, namely ERCC1, ERCC3, ERCC5 and XPC, and found a reduction in expression in at least one gene in more than 20% of the MDS samples when compared to normal samples. Additionally, patients with high risk MDS were more likely to have a reduction in NER gene expression [42]. The authors suggested that such a decrease in DNA repair gene expression may predispose individuals to chromosomal instability and underlie the pathophysiology of the disease.

The ERCC2 (XPD) gene harbours a lys to gln change at codon 751 [72]. Like many of the polymorphisms in DNA repair genes the functional consequences of the ERCC-751gln variant allele are still unclear and a review of the literature by Clarkson and Wood [18] questions whether a causal relationship between the ERCC2 gene and reduced DNA repair occurs; instead the SNP may be in linkage with another functional SNP. Whatever the consequences, the ERCC2-751gln homozygote variant has been associated with a significant increase of developing chemotherapy-induced t-AML/MDS (OR 2.22, 95% CI 1.04–4.74) [3].

## ***Mismatch Repair***

Mismatch repair (MMR) corrects mismatched DNA bases that can result from misincorporation errors that have avoided polymerase proof-reading activity during DNA replication. In addition MMR can also process some types of DNA damage. MMR is reasonably easy to study because deficiencies in the pathway result in an elevated rate of mutations which can be measured in simple repetitive DNA sequences (microsatellites). There have been a number of studies which have searched for MMR deficiency (microsatellite instability; MSI) in both de novo MDS and t-MDS/AML. A summary of the de novo MDS studies is shown in Table 2.2. Noteworthy is the study by Kaneko et al. (Table 2.2) because serial samples from the same patients were analysed demonstrating that MSI, when it occurs, is an early event and may then contribute to the pathogenesis of MDS.

There are also a large number of studies looking at the incidence of MSI in t-AML/MDS (reviewed in Seedhouse and Russell [67]). The incidence in the t-AML/MDS samples is much higher (approximately 50%) than for de novo MDS suggesting that a prerequisite of MSI in MDS is a significant burden of DNA damage. Along these lines is work done on the development of AML/MDS following azathioprine immunosuppressive treatment after organ transplant: Offman et al. proposed that AML/MDS development may reflect the selection and expansion of MMR-deficient clones within the bone marrow which are resistant to drug-induced damage. The lack of MMR is expected to lead to the accumulation of mutations

**Table 2.2** Summary of microsatellite instability (MSI) studies in de novo MDS

Number of samples	Number of loci studied (up to)	% of samples with MSI <sup>a</sup>	Reference
6	4	33	[34]
19	10	16	[35]
9	22	11	[39]
12	12	8 <sup>b</sup>	[71]
7	14	0	[12]
23	18	4 <sup>b</sup>	[49]
29	10	0 <sup>b</sup>	[48]
23	9	0 <sup>b</sup>	[28]

<sup>a</sup> The proportion of loci showing MSI differs between studies.

<sup>b</sup> Results are shown for two or more loci displaying MSI and results indicate further samples have MSI at just one locus

which may subsequently result in a clonal haematopoietic disorder [58]. Further support of the importance of MMR in t-AML/MDS is a study showing that the variant allele of the MSH2 IVS12-6 T to C polymorphism [25] is over-represented in t-AML/MDS patients who had previously received alkylating therapy (OR 4.02, 95% CI 1.4–11.37) [88]. Strikingly both of the t-MDS/AML variant homozygotes had MSI, although not all of the MSI-positive samples had the polymorphism. The functional consequence of the polymorphism is unknown, although it resides in the splice acceptor site of exon 13 and may therefore alter splice site recognition.

## Discussion

Protection from DNA damage, either by preventing (detoxification or apoptosis) or repairing it, is paramount in keeping our cells healthy and this is particularly so for haematopoietic stem and progenitor cells which often come into close proximity to damaging agents. An accumulation of unrepaired genomic damage in HSCs will result in an increased risk of a clonal stem cell disease. MDS is a disease characterised by DNA damage and genetic instability, a state that is expressed as gross karyotypic abnormalities in 50% of patients. Whilst many polymorphisms only have subtle functional effects, gene-environment interactions are likely to magnify these effects making polymorphisms worthwhile of study. We are now accumulating evidence demonstrating a contribution of polymorphisms in detoxification pathways and DNA repair pathways to MDS susceptibility, however there is still more work to be done.

### *Sample Size and Controls for Polymorphism Studies*

Much of the work on susceptibility to MDS has focused on polymorphisms in the DNA repair and detoxification genes. Many of the polymorphic genes have only been investigated in single small studies, whilst those polymorphisms which have